Prolonged Omicron-specific B cell maturation alleviates immune imprinting induced by SARS-CoV-2 inactivated vaccine

Emerg Microbes Infect. 2024 Dec;13(1):2412623. doi: 10.1080/22221751.2024.2412623. Epub 2024 Oct 15.

Abstract

SARS-CoV-2 ancestral strain-induced immune imprinting poses great challenges to updating vaccines for new variants. Studies showed that repeated Omicron exposures could override immune imprinting induced by inactivated vaccines but not mRNA vaccines, a disparity yet to be understood. Here, we analyzed the immune imprinting alleviation in inactivated vaccine (CoronaVac) cohorts after a long-term period following breakthrough infections (BTI). We observed in CoronaVac-vaccinated individuals who experienced BA.5/BF.7 BTI, the proportion of Omicron-specific memory B cells (MBCs) substantially increased after an extended period post-Omicron BTI, with their antibodies displaying enhanced somatic hypermutation and neutralizing potency. Consequently, the neutralizing antibody epitope distribution encoded by MBCs post-BA.5/BF.7 BTI after prolonged maturation closely mirrors that in BA.5/BF.7-infected unvaccinated individuals. Together, these results indicate the activation and expansion of Omicron-specific naïve B cells generated by first-time Omicron exposure helped to alleviate CoronaVac-induced immune imprinting, and the absence of this process should have caused the persistent immune imprinting seen in mRNA vaccine recipients.

Keywords: Omicron breakthrough infection; SARS-CoV-2 RBD; antibody responses; epitope distribution; immune imprinting.

MeSH terms

  • Antibodies, Neutralizing* / blood
  • Antibodies, Neutralizing* / immunology
  • Antibodies, Viral* / blood
  • Antibodies, Viral* / immunology
  • B-Lymphocytes / immunology
  • Breakthrough Infections
  • COVID-19 Vaccines* / administration & dosage
  • COVID-19 Vaccines* / immunology
  • COVID-19* / immunology
  • COVID-19* / prevention & control
  • COVID-19* / virology
  • Female
  • Humans
  • Memory B Cells / immunology
  • SARS-CoV-2* / genetics
  • SARS-CoV-2* / immunology
  • Vaccines, Inactivated* / administration & dosage
  • Vaccines, Inactivated* / immunology

Substances

  • COVID-19 Vaccines
  • Antibodies, Viral
  • Vaccines, Inactivated
  • Antibodies, Neutralizing
  • SARS-CoV-2 inactivated vaccines

Supplementary concepts

  • SARS-CoV-2 variants
  • COVID-19 breakthrough infections

Grants and funding

This study was financially supported by the Ministry of Science and Technology of China (grant number: 2021D0102), National Natural Science Foundation of China (grant number: 32222030), and Changping Laboratory (grant number: 2021A0201).